Insider · CIK 0001184421
Kevin Rakin
Files at ELUT (AZIYO BIOLOGICS, INC.), QSI (Quantum-Si Inc). First filing Dec 19, 2025, latest Feb 2, 2026.
In brief
Kevin Rakin files SEC Form 4 as director and 10% owner at ELUT (AZIYO BIOLOGICS, INC.), and also at QSI (Quantum-Si Inc). Since Dec 19, 2025, Kevin Rakin has reported 2 open-market buys worth $100k and 0 open-market sells worth $0, the latest filed on Feb 2, 2026.
A track record needs three past buys with six months of prices behind them; Kevin Rakin has 0, so none is measured yet.
The newest scored trade: bought $74k of ELUT on Jan 30, 2026, filed Feb 2, 2026, scored 54 (moderate). In the last 12 months: 2 buys worth $100k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ELUT: AZIYO BIOLOGICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | AZIYO BIOLOGICS, INC. | $74k 70,000 shares | +56% | +108% from low-68% from high | |
| 56Moderate | AZIYO BIOLOGICS, INC. | $26k 50,000 shares | +18% | 0% from low-90% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | ELUT AZIYO BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +159,590 | $0.00 | $0 | 159,590 | Jun 15, 2026 |
| Jun 1, 2026 | ELUT AZIYO BIOLOGICS, INC. | GGift Class A Common Stock | -70,000 | $0.00 | $0 | 126,120 | Jun 2, 2026 |
| Jun 1, 2026 | ELUT AZIYO BIOLOGICS, INC. | JOther Class A Common Stockindirect: By trusts | -50,000 | $0.00 | $0 | 272,419 | Jun 2, 2026 |
| May 18, 2026 | QSI Quantum-Si Inc | AGrant or award Stock Option (right to buy)derivative | +251,185 | $0.00 | $0 | 251,185 | May 20, 2026 |
| Jan 30, 2026 | ELUT AZIYO BIOLOGICS, INC. | POpen-market purchase Class A Common Stock | +70,000 | $1.06 | $74k | 196,120 | Feb 2, 2026 |
| Dec 17, 2025 | ELUT AZIYO BIOLOGICS, INC. | POpen-market purchase Class A Common Stockindirect: By trusts | +50,000 | $0.52 | $26k | 322,419 | Dec 19, 2025 |
| Dec 11, 2025 | ELUT AZIYO BIOLOGICS, INC. | JOther Class A Common Stockindirect: See footnotes | -4,505,941 | - | - | 4,978,978 | Dec 19, 2025 |
| Dec 11, 2025 | ELUT AZIYO BIOLOGICS, INC. | JOther Class A Common Stockindirect: See footnotes | -4,505,941 | - | - | 4,978,978 | Dec 17, 2025 |
| Dec 11, 2025 | ELUT AZIYO BIOLOGICS, INC. | JOther Class A Common Stockindirect: See footnotes | -4,372,497 | - | - | 4,978,978 | Dec 15, 2025 |
| May 29, 2025 | ELUT AZIYO BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +90,509 | $0.00 | $0 | 90,509 | Jun 2, 2025 |
| May 19, 2025 | QSI Quantum-Si Inc | AGrant or award Stock Option (right to buy)derivative | +126,095 | $0.00 | $0 | 126,095 | May 21, 2025 |
| Jun 6, 2024 | ELUT AZIYO BIOLOGICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +47,753 | $0.00 | $0 | 47,753 | Jun 10, 2024 |
| May 16, 2024 | QSI Quantum-Si Inc | AGrant or award Stock Option (right to buy)derivative | +113,281 | $0.00 | $0 | 113,281 | May 17, 2024 |
Questions about Kevin Rakin
Answered from the filings on this page, as of the latest one.
Is Kevin Rakin buying or selling?
In the last 12 months Kevin Rakin reported 2 open-market buys worth $100k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $74k of ELUT on Jan 30, 2026. Grants, option exercises and tax withholding are not counted.
How did Kevin Rakin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin Rakin has 0.
Where does Kevin Rakin file Form 4?
Kevin Rakin has filed Form 4 at ELUT (AZIYO BIOLOGICS, INC.); QSI (Quantum-Si Inc). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.